71 results
8-K
EX-99.1
KA
Kineta Inc
21 Mar 24
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
4:04pm
, underscoring the potential of KVA12123 as a next-generation immunotherapy. We truly appreciate the efforts of the healthcare professionals, the patients
8-K
EX-99.1
KA
Kineta Inc
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
of Kineta. “We appreciate the patients and healthcare providers that are participating in this important study, and we look forward to further evaluating
8-K
KA
Kineta Inc
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
Chief Executive Officer, Shawn Iadonato, Ph.D., will present at the Jefferies Healthcare Conference, to be held in New York, NY on June 7-9, 2023
8-K
EX-99.1
0v08zt5l4 bbm
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am
8-K
EX-99.1
8bahaym3so9ybzeq0txo
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
ahiu4
3 Apr 23
Kineta to Present at 22nd Annual Needham Healthcare Conference
7:01am
8-K
EX-99.6
18gb6p
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
EX-99.5
r3m a9boe
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
8-K
xvuc fc4fkh
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
424B3
0znkl1rs5iip
10 Nov 22
Prospectus supplement
4:21pm